CER Making Its Mark in Health Care Marketplace

from tHEORetically Speaking: The HealthEconomics.Com Blog at http://bit.ly/2tqISKh on June 29, 2017 at 06:34PM

Although comparative effectiveness research (CER) is still a relatively recent scientific discipline, its rapid expansion has helped thrust it into the spotlight.

story_ftr_imageInternational Society For Pharmacoeconomics and Outcomes Research Chief Science Officer Dr. Richard Wilke says a core principle of CER is its focus on effectiveness rather efficacy. Through CER, researchers can “measure the degree of beneficial effect under ‘real-world’ clinical settings,” according to Wilke.

Wilke says one of CER’s strong points its ability to add “real-world decision-making value at both the micro level … and at the macro level.”

“The results of well-designed CER studies provide value to decision makers throughout the international community, but are particularly important to those in the United States, where regulatory approval for new-molecule pharmaceutical products is typically based primarily or exclusively on (random clinical trials) using placebo-controlled or non-inferiority study designs,” Wilke writes in ISPOR’s Value and Outcomes Spotlight.

Although CER studies are conducted by non-governmental entities, the federal government often sponsors larger prospective CER studies, which are “limited in number and scope,” according to Wilke, and more expensive.

Read Willke’s full report in ISPOR’s Values and Outcomes Spotlight by clicking here.